Wu Qi-Jun, Li Yuan-Yuan, Tu Chao, Zhu Jingjing, Qian Ke-Qing, Feng Tong-Bao, Li Changwei, Wu Lang, Ma Xiao-Xin
Department of Clinical Epidemiology, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning, China.
Department of Hematology, the Affiliated Hospital of Xuzhou Medical College, Xuzhou, Jiangsu, 221000, China.
Sci Rep. 2015 Sep 16;5:14243. doi: 10.1038/srep14243.
The association between parity and endometrial cancer risk is inconsistent from observational studies. We aimed to quantitatively assess the relationship by summarizing all relevant epidemiological studies. PubMed (MEDLINE), Embase and Scopus were searched up to February 2015 for eligible case-control studies and prospective studies. Random-effects model was used to pool risk estimations. Ten prospective studies, 35 case-control studies and 1 pooled analysis of 10 cohort and 14 case-control studies including 69681 patients were identified. Pooled analysis revealed that there was a significant inverse association between parity and risk of endometrial cancer (relative risk (RR) for parous versus nulliparous: 0.69, 95% confidence interval (CI) 0.65-0.74; I(2) = 76.9%). By evaluating the number of parity, we identified that parity number of 1, 2 or 3 versus nulliparous demonstrated significant negative association (RR = 0.73, 95% CI 0.64-0.84, I(2) = 88.3%; RR = 0.62, 95% CI 0.53-0.74, I(2) = 92.1%; and RR = 0.68, 95% CI 0.65-0.70, I(2) = 20.0% respectively). The dose-response analysis suggested a nonlinear relationship between the number of parity and endometrial cancer risk. The RR decreased when the number of parity increased. This meta-analysis suggests that parity may be associated with a decreased risk of endometrial cancer. Further studies are warranted to replicate our findings.
观察性研究中,产次与子宫内膜癌风险之间的关联并不一致。我们旨在通过总结所有相关的流行病学研究来定量评估二者之间的关系。截至2015年2月,我们在PubMed(MEDLINE)、Embase和Scopus数据库中检索了符合条件的病例对照研究和前瞻性研究。采用随机效应模型汇总风险估计值。共纳入10项前瞻性研究、35项病例对照研究以及1项对10个队列研究和14项病例对照研究的汇总分析,涉及69681例患者。汇总分析显示,产次与子宫内膜癌风险之间存在显著的负相关(经产与未产的相对风险(RR):0.69,95%置信区间(CI)0.65 - 0.74;I² = 76.9%)。通过评估产次数量,我们发现产次为1、2或3与未产相比均呈现显著的负相关(RR = 0.73,95% CI 0.64 - 0.84,I² = 88.3%;RR = 0.62,95% CI 0.53 - 0.74,I² = 92.1%;RR = 0.68,95% CI 0.65 - 0.70,I² = 20.0%)。剂量反应分析表明,产次数量与子宫内膜癌风险之间存在非线性关系。随着产次数量增加,RR值降低。这项荟萃分析表明,产次可能与子宫内膜癌风险降低相关。有必要开展进一步研究以验证我们的研究结果。